title: Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma.
abstract: Two earlier studies resulted in the design of a phase II trial of 41.8 degrees C (x 60 min) extracorporeal whole body hyperthermia (WBH) with ICE, i.e. ifosfamide (5 g/m2), carboplatin (300 mg/m2), and etoposide given with WBH, as well as, day 2 and 3 post-WBH (100 mg/m2) for adult patients with refractory sarcoma. 12 patients entered this trial; all were evaluable. 8 patients had a history of prior chemotherapy associated with disease progression. Following WBH/ICE, 7 partial remissions were observed (58%); 3 patients experienced disease stabilisation; the aforementioned 10 patients each received four cycles of therapy. 2 patients exhibited progressive disease. Episodes of WHO graded (grade 3; grade 4) toxicity observed included: anaemia (2;2); leucopenia (5;7); thrombocytopenia (1;6); renal (0;1). Other toxicities (grade 1 and 2) included: anasarca, diarrhoea, ventricular arrhythmias, pressure sores, and perioral herpes simplex.
authors.affiliation: Department of Internal Medicine, Medical University of Lübeck, Germany.
authors.forename: G J
authors.initials: GJ
authors.lastname: Wiedemann
authors.forename: H I
authors.initials: HI
authors.lastname: Robins
authors.forename: S
authors.initials: S
authors.lastname: Gutsche
authors.forename: M
authors.initials: M
authors.lastname: Mentzel
authors.forename: M
authors.initials: M
authors.lastname: Deeken
authors.forename: D M
authors.initials: DM
authors.lastname: Katschinski
authors.forename: S
authors.initials: S
authors.lastname: Eleftheriadis
authors.forename: R
authors.initials: R
authors.lastname: Crahé
authors.forename: C
authors.initials: C
authors.lastname: Weiss
authors.forename: B
authors.initials: B
authors.lastname: Storer
authors.forename: T
authors.initials: T
authors.lastname: Wagner
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012509:Sarcoma / Q000188:drug therapy / Q000628:therapy*
chemical_list: D005047:Etoposide; D016190:Carboplatin; D007069:Ifosfamide